KR20070108247A - 프롤린 유도체의 염 또는 그 용매화물 및 그 제조 방법 - Google Patents
프롤린 유도체의 염 또는 그 용매화물 및 그 제조 방법 Download PDFInfo
- Publication number
- KR20070108247A KR20070108247A KR1020077021144A KR20077021144A KR20070108247A KR 20070108247 A KR20070108247 A KR 20070108247A KR 1020077021144 A KR1020077021144 A KR 1020077021144A KR 20077021144 A KR20077021144 A KR 20077021144A KR 20070108247 A KR20070108247 A KR 20070108247A
- Authority
- KR
- South Korea
- Prior art keywords
- acid
- salt
- solvate
- ylcarbonyl
- hydrate
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
Claims (33)
- 3-{(2S,4S)-4-[4-(3-메틸-1-페닐-1H-피라졸-5-일)피페라진-1-일]피롤리딘-2-일카르보닐}티아졸리딘과 유기 또는 무기의 1 내지 3염기산과의 염 또는 그 용매화물.
- 제1항에 있어서, 유기 또는 무기의 1염기산이 염산, 브롬화수소산, 질산, 메실산, 토실산, 베실산, 염산, 나프탈렌-1-술폰산, 나프탈렌-2-술폰산, 몰식자산 또는 캄파술폰산인(단, 1염기산이 염산인 경우, 염은 2 또는 2.5염산염임) 염 또는 그 용매화물.
- 제1항에 있어서, 유기 또는 무기의 2염기산이 푸마르산, 말레산, 황산, 숙신산, L-타르타르산, 에탄디술폰산 또는 시트르산인 염 또는 그 용매화물.
- 제1항에 있어서, 유기 또는 무기의 3염기산이 인산인 염 또는 그 용매화물.
- 제1항에 있어서, 2.0브롬화수소산, 2.5브롬화수소산, 2말레산, 2토실산, 2베실산, 2염산, 2.5염산, 2나프탈렌-1-술폰산, 2나프탈렌-2-술폰산, 2캄파술폰산, 푸마르산, 황산, 숙신산, L-타르타르산 또는 시트르산과의 염인 염 또는 그 용매화물.
- 제5항에 있어서, 2.0브롬화수소산, 2.5브롬화수소산, 2말레산, 2토실산, 2.5염산, 2나프탈렌-1-술폰산, 2메실산, 3메실산 또는 2나프탈렌-2-술폰산과의 염인 염 또는 그 용매화물.
- 주위 온도에서의 물에 대한 용해도가 7 ㎎/㎖ 내지 2 g/㎖인 1염기산과 3-{(2S,4S)-4-[4-(3-메틸-1-페닐-1H-피라졸-5-일)피페라진-1-일]피롤리딘-2-일카르보닐}티아졸리딘과의 염 또는 그 용매화물.
- 제7항에 있어서, 37℃에서의 물에 대한 용해도가 20 ㎎/㎖ 이상인 염 또는 그 용매화물.
- 제7항에 있어서, pH 9∼12에서의 물에 대한 용해도가 7 ㎎/㎖인 염 또는 그 용매화물.
- 제1항에 있어서, 25℃에서 측정한 흡습성이 6% 이하인 염 또는 그 용매화물.
- 제10항에 있어서, 25℃에서 측정한 상대 습도 0%∼50% 범위에서의 흡습성이 5%인 염 또는 그 용매화물.
- 제10항에 있어서, 25℃에서 측정한 상대 습도 5%∼90% 범위에서의 흡습성이 2%인 염 또는 그 용매화물.
- 제10항 내지 제12항 중 어느 한 항에 있어서, 염이 제2항에 기재한 1염기성산과의 염인 염 또는 그 용매화물.
- 3-{(2S,4S)-4-[4-(3-메틸-1-페닐-1H-피라졸-5-일)피페라진-1-일]피롤리딘-2-일카르보닐}티아졸리딘·2.5브롬화수소산염 또는 그 용매화물.
- 제14항에 있어서, 분말 X선 회절 패턴에 있어서, 2θ로 표시되는 회절 각도로서 5.4°, 13.4° 및 14.4°(각각 ±0.2°)에 피크를 갖는 것을 특징으로 하는 염 또는 그 수화물.
- 제15항에 있어서, 1.0∼2.0 수화물인 수화물.
- 제14항에 있어서, 분말 X선 회절 패턴에 있어서, 2θ로 표시되는 회절 각도로서, 5.4°, 13.4°, 14.4°, 22.6° 및 26.5°(각각 ±0.2°)에 피크를 갖는 것을 특징으로 하는 염 또는 그 수화물.
- 제17항에 있어서, 1.0 내지 2.0 수화물인 수화물.
- 제14항에 있어서, 도 1에 예시되는 분말 X선 회절 패턴을 나타내는 염 또는 그 수화물.
- 3-{(2S,4S)-4-[4-(3-메틸-1-페닐-1H-피라졸-5-일)피페라진-1-일]피롤리딘-2-일카르보닐}티아졸리딘·2.0브롬화수소산염 또는 그 용매화물.
- 제20항에 있어서, 분말 X선 회절 패턴에 있어서, 2θ로 표시되는 회절 각도로서 5.7°, 7.7°, 11.3°, 16.2° 및 17.0°(각각 ±0.2°)에 피크를 갖는 것을 특징으로 하는 염의 수화물.
- 제20항에 있어서, 분말 X선 회절 패턴에 있어서, 2θ로 표시되는 회절 각도로서 5.2°, 10.4°, 19.1°, 19.8° 및 20.7°(각각 ±0.2°)에 피크를 갖는 것을 특징으로 하는 염의 수화물.
- 제20항에 있어서, 분말 X선 회절 패턴에 있어서, 2θ로 표시되는 회절 각도로서 5.5°, 13.4°, 14.3°, 21.4° 및 26.7°(각각 ±0.2°)에 피크를 갖는 것을 특징으로 하는 염의 수화물.
- 제20항에 있어서, 도 2에 예시되는 분말 X선 회절 패턴을 나타내는 염의 수 화물.
- 제20항에 있어서, 도 3에 예시되는 분말 X선 회절 패턴을 나타내는 염의 수화물.
- 제20항에 있어서, 도 4에 예시되는 분말 X선 회절 패턴을 나타내는 염의 수화물.
- 3-{(2S,4S)-1-(1,1-디메틸에틸옥시카르보닐)-4-[4-(3-메틸-1-페닐-1H-피라졸-5-일)피페라진-1-일]피롤리딘-2-일카르보닐}티아졸리딘에 대하여 브롬화수소산으로 탈1,1-디메틸에틸옥시카르보닐 반응을 행하는 동시에 조염(造鹽)을 행하는 것을 특징으로 하는 3-{(2S,4S)-4-[4-(3-메틸-1-페닐-1H-피라졸-5-일)피페라진-1-일]피롤리딘-2-일카르보닐}티아졸리딘·2.5브롬화수소산염 또는 그 용매화물의 제조 방법.
- 3-{(2S,4S)-4-[4-(3-메틸-1-페닐-1H-피라졸-5-일)피페라진-1-일]피롤리딘-2-일카르보닐}티아졸리딘·2.5브롬화수소산염을, 허용되는 용매를 이용하여 결정화하는 공정을 포함하는 3-{(2S,4S)-4-[4-(3-메틸-1-페닐-1H-피라졸-5-일)피페라진-1-일]피롤리딘-2-일카르보닐}티아졸리딘·2.5브롬화수소산염 또는 그 용매화물의 제조 방법.
- 제28항에 있어서, 허용되는 용매가 물 및/또는 "잔류 용매 Q3C의 ICH 가이드 라인"에 있어서 1일 섭취 허용량("PDE")이 10 ㎎/day를 초과하는 용매로부터 선택되는 용매인 방법.
- 제28항에 있어서, 허용되는 용매가 물 및/또는 "잔류 용매 Q3C의 ICH 가이드 라인"에 있어서의 클래스 3의 용매로부터 선택되는 용매인 방법.
- 제28항에 있어서, 허용되는 용매가 에탄올, 1-프로판올, 2-프로판올, 아세트산에틸, 아세톤으로부터 선택되는 용매인 방법.
- 제28항에 있어서, 허용되는 용매가 에탄올 및/또는 물인 방법.
- 3-{(2S,4S)-4-[4-(3-메틸-1-페닐-1H-피라졸-5-일)피페라진-1-일]피롤리딘-2-일카르보닐}티아졸리딘·2.5브롬화수소산염의 1.0 내지 2.0 수화물.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005041851 | 2005-02-18 | ||
JPJP-P-2005-00041851 | 2005-02-18 | ||
PCT/JP2006/302827 WO2006088129A1 (ja) | 2005-02-18 | 2006-02-17 | プロリン誘導体の塩、またはその溶媒和物、及びその製造方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020137016412A Division KR20130076903A (ko) | 2005-02-18 | 2006-02-17 | 프롤린 유도체의 염 또는 그 용매화물 및 그 제조 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070108247A true KR20070108247A (ko) | 2007-11-08 |
KR101352650B1 KR101352650B1 (ko) | 2014-01-16 |
Family
ID=36916526
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077021144A KR101352650B1 (ko) | 2005-02-18 | 2006-02-17 | 프롤린 유도체의 염 또는 그 용매화물 및 그 제조 방법 |
KR1020137016412A KR20130076903A (ko) | 2005-02-18 | 2006-02-17 | 프롤린 유도체의 염 또는 그 용매화물 및 그 제조 방법 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020137016412A KR20130076903A (ko) | 2005-02-18 | 2006-02-17 | 프롤린 유도체의 염 또는 그 용매화물 및 그 제조 방법 |
Country Status (14)
Country | Link |
---|---|
US (2) | US8003790B2 (ko) |
EP (2) | EP2602259A3 (ko) |
JP (3) | JP4208938B2 (ko) |
KR (2) | KR101352650B1 (ko) |
CN (3) | CN101119991B (ko) |
AU (1) | AU2006215041B2 (ko) |
BR (1) | BRPI0607863B8 (ko) |
CA (1) | CA2598301C (ko) |
EA (1) | EA013119B1 (ko) |
ES (1) | ES2588164T3 (ko) |
MX (1) | MX2007010054A (ko) |
NZ (1) | NZ561489A (ko) |
TW (1) | TWI403511B (ko) |
WO (1) | WO2006088129A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200040570A (ko) * | 2018-10-10 | 2020-04-20 | 주식회사 파마코스텍 | 테네리글립틴 2토실산염 2수화물의 결정형 ⅰ형 및 그 제조방법 |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2602259A3 (en) * | 2005-02-18 | 2014-09-10 | Mitsubishi Tanabe Pharma Corporation | Salt of proline derivative, solvate thereof, and production method thereof |
MX2007013301A (es) * | 2005-04-26 | 2008-03-07 | Mitsubishi Tanabe Pharma Corp | Agente profilactico/terapeutico para la anormalidades del metabolismo del azucar/lipidos. |
US8927504B2 (en) | 2007-04-03 | 2015-01-06 | Mitsubishi Tanabe Pharma Corporation | Combined use of dipeptidyl peptidase 4 inhibitor and sweetener |
CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
EA031225B1 (ru) | 2008-08-15 | 2018-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Ингибиторы дпп-4 для заживления ран |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
JP2012517977A (ja) | 2009-02-13 | 2012-08-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dpp−4阻害剤(リナグリプチン)を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬 |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
ES2760917T3 (es) | 2009-11-27 | 2020-05-18 | Boehringer Ingelheim Int | Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina |
EP2514422B1 (en) * | 2009-12-18 | 2016-08-10 | Mitsubishi Tanabe Pharma Corporation | Elution stabilized teneligliptin preparation |
US20130109703A1 (en) | 2010-03-18 | 2013-05-02 | Boehringer Ingelheim International Gmbh | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions |
BR112012025592A2 (pt) | 2010-04-06 | 2019-09-24 | Arena Pharm Inc | moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos |
JP6034781B2 (ja) | 2010-05-05 | 2016-11-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 併用療法 |
EA201991014A1 (ru) | 2010-06-24 | 2019-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение диабета |
SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
JP5863789B2 (ja) * | 2011-06-01 | 2016-02-17 | 田辺三菱製薬株式会社 | ピラゾール誘導体の製造方法 |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
KR20140059236A (ko) | 2011-08-19 | 2014-05-15 | 머크 샤프 앤드 돔 코포레이션 | Hcv 프로테아제 억제제의 결정 형태 |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
MX370649B (es) * | 2012-08-31 | 2019-12-19 | Glenmark Pharmaceuticals Ltd | Proceso para la preparacion de teneligliptina. |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
CN104230917B (zh) * | 2013-06-24 | 2017-04-05 | 南京华威医药科技开发有限公司 | 一种脯氨酸衍生物盐的水合物及其生产方法 |
WO2015019238A1 (en) | 2013-08-06 | 2015-02-12 | Ranbaxy Laboratories Limited | Process for the preparation of n-protected (5s)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-one |
WO2015019239A1 (en) | 2013-08-06 | 2015-02-12 | Ranbaxy Laboratories Limited | Process for the preparation of 1-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazine |
WO2015063709A1 (en) | 2013-10-31 | 2015-05-07 | Ranbaxy Laboratories Limited | Process for the preparation of 1-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazine |
CN104650065A (zh) * | 2013-11-22 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 一种替格列汀化合物 |
WO2015173779A1 (en) | 2014-05-16 | 2015-11-19 | Micro Labs Limited | Process for the preparation of teneligliptin and its novel intermediates |
CN105294673B (zh) * | 2014-06-18 | 2018-04-13 | 四川科伦药物研究院有限公司 | 一种氢溴酸替格列汀的合成方法 |
JP2019512460A (ja) * | 2017-02-03 | 2019-05-16 | グレンマーク・ファーマシューティカルズ・リミテッド | テネリグリプチンのシュウ酸塩およびその溶媒和物を含む製剤 |
CN108727364A (zh) * | 2017-04-18 | 2018-11-02 | 乳源东阳光药业有限公司 | 一种氢溴酸替格列汀无定型及其制备方法 |
WO2019205021A1 (zh) * | 2018-04-25 | 2019-10-31 | 乳源东阳光药业有限公司 | 一种氢溴酸替格列汀无定型及其制备方法 |
KR20200127480A (ko) | 2019-05-02 | 2020-11-11 | 연성정밀화학(주) | 테네리글립틴 에디실산염 결정형 및 이의 제조방법 |
KR20210121421A (ko) | 2020-03-30 | 2021-10-08 | 코오롱생명과학 주식회사 | 테네리글리프틴 2.5브롬화수소산염 무정형의 제조방법 |
JP2022069426A (ja) * | 2020-10-23 | 2022-05-11 | マイラン ラボラトリーズ リミテッド | テネリグリプチン2.5臭化水素酸塩のアモルファスを調製する方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1062357A (en) * | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
US4337341A (en) * | 1976-11-02 | 1982-06-29 | Eli Lilly And Company | 4a-Aryl-octahydro-1H-2-pyrindines |
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
US6090786A (en) * | 1994-06-10 | 2000-07-18 | Fondatech Benelux N.V. | Serine proteases, their activity and their synthetic inhibitors |
DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
US20030176357A1 (en) * | 1998-10-06 | 2003-09-18 | Pospisilik Andrew J. | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels |
WO2001055105A1 (en) | 2000-01-24 | 2001-08-02 | Novo Nordisk A/S | N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
HUP0301622A3 (en) | 2000-07-04 | 2006-05-29 | Novo Nordisk As | Purine derivatives inhibiting the enzyme dipeptidyl petidase iv (dpp-iv) and pharmaceutical compositions containing them |
ES2311534T3 (es) | 2000-08-10 | 2009-02-16 | Mitsubishi Tanabe Pharma Corporation | Derivados de prolina y su uso como farmacos. |
PL364221A1 (en) | 2001-02-02 | 2004-12-13 | Takeda Chemical Industries, Ltd. | Fused heterocyclic compounds |
GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
US20040259883A1 (en) * | 2001-09-14 | 2004-12-23 | Hiroshi Sakashita | Thiazolidine derivative and medicinal use thereof |
US20040229848A1 (en) * | 2003-05-05 | 2004-11-18 | Hans-Ulrich Demuth | Glutaminyl based DP IV-inhibitors |
AU2003902946A0 (en) * | 2003-06-12 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
JP4569802B2 (ja) | 2003-07-23 | 2010-10-27 | 眞 八藤 | ビタミンを主材とするイオン化ミネラル結合型サプリメントの製造方法 |
EP2602259A3 (en) * | 2005-02-18 | 2014-09-10 | Mitsubishi Tanabe Pharma Corporation | Salt of proline derivative, solvate thereof, and production method thereof |
MX2007013301A (es) | 2005-04-26 | 2008-03-07 | Mitsubishi Tanabe Pharma Corp | Agente profilactico/terapeutico para la anormalidades del metabolismo del azucar/lipidos. |
EP1894567B1 (en) | 2005-06-03 | 2012-08-15 | Mitsubishi Tanabe Pharma Corporation | Concomitant pharmaceutical agents and use thereof |
-
2006
- 2006-02-17 EP EP13157384.2A patent/EP2602259A3/en not_active Withdrawn
- 2006-02-17 MX MX2007010054A patent/MX2007010054A/es active IP Right Grant
- 2006-02-17 EP EP06713968.3A patent/EP1854795B1/en not_active Not-in-force
- 2006-02-17 US US11/816,493 patent/US8003790B2/en not_active Expired - Fee Related
- 2006-02-17 AU AU2006215041A patent/AU2006215041B2/en not_active Ceased
- 2006-02-17 ES ES06713968.3T patent/ES2588164T3/es active Active
- 2006-02-17 EA EA200701756A patent/EA013119B1/ru not_active IP Right Cessation
- 2006-02-17 TW TW095105368A patent/TWI403511B/zh not_active IP Right Cessation
- 2006-02-17 BR BRPI0607863A patent/BRPI0607863B8/pt not_active IP Right Cessation
- 2006-02-17 KR KR1020077021144A patent/KR101352650B1/ko active IP Right Review Request
- 2006-02-17 CN CN2006800048659A patent/CN101119991B/zh not_active Ceased
- 2006-02-17 CN CN2011103035812A patent/CN102372705A/zh active Pending
- 2006-02-17 KR KR1020137016412A patent/KR20130076903A/ko not_active Application Discontinuation
- 2006-02-17 NZ NZ561489A patent/NZ561489A/en not_active IP Right Cessation
- 2006-02-17 CN CN201110303552.6A patent/CN102372704B/zh active Active
- 2006-02-17 CA CA2598301A patent/CA2598301C/en not_active Expired - Fee Related
- 2006-02-17 JP JP2007503744A patent/JP4208938B2/ja active Active
- 2006-02-17 WO PCT/JP2006/302827 patent/WO2006088129A1/ja active Application Filing
-
2008
- 2008-04-30 JP JP2008119236A patent/JP2008214358A/ja active Pending
-
2011
- 2011-07-29 US US13/194,501 patent/US8604198B2/en not_active Expired - Fee Related
-
2012
- 2012-10-10 JP JP2012224923A patent/JP2013032376A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200040570A (ko) * | 2018-10-10 | 2020-04-20 | 주식회사 파마코스텍 | 테네리글립틴 2토실산염 2수화물의 결정형 ⅰ형 및 그 제조방법 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101352650B1 (ko) | 프롤린 유도체의 염 또는 그 용매화물 및 그 제조 방법 | |
EP2343296A1 (en) | A process for the purification of paliperidone | |
TW202112768A (zh) | 二取代吡唑化合物 | |
KR20150108384A (ko) | 중추신경계 질병의 치료를 위한 옥시토신 수용체 작용제 | |
KR20070046878A (ko) | 5-ht7 수용체 안타고니스트 | |
ES2257168B1 (es) | Ligandos del receptor 5-ht7. | |
JP7182562B2 (ja) | 2-([1,2,3]トリアゾール-2-イル)-安息香酸誘導体の製造 | |
KR101651994B1 (ko) | 아릴옥시 아제티딘 화합물, 및 이를 포함하는 약학 조성물 | |
CN116406364A (zh) | 用于治疗红细胞障碍和炎性疾病的四氢异喹啉衍生物 | |
KR20110023887A (ko) | CBı-길항 활성을 갖는 플루오로-치환된 3,4-디아릴-4,5-디하이드로-1H-피라졸-1-카복스아미딘 유도체 | |
ES2257167B1 (es) | Inhibidores del receptor 5-ht7. | |
JP2024028642A (ja) | カンナビノイド受容体部分アゴニストとしてのインダゾール誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
N231 | Notification of change of applicant | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
A107 | Divisional application of patent | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
A101 | Application to extend term of patent right by permit | ||
J204 | Request for invalidation trial [patent] | ||
J204 | Request for invalidation trial [patent] | ||
J121 | Written withdrawal of request for trial | ||
J501 | Disposition of invalidation of trial | ||
J501 | Disposition of invalidation of trial | ||
J501 | Disposition of invalidation of trial | ||
J121 | Written withdrawal of request for trial | ||
J501 | Disposition of invalidation of trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
FPAY | Annual fee payment |
Payment date: 20161220 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20171219 Year of fee payment: 5 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J121 | Written withdrawal of request for trial | ||
FPAY | Annual fee payment |
Payment date: 20181226 Year of fee payment: 6 |
|
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2018100003538; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20181101 Effective date: 20191231 Free format text: TRIAL NUMBER: 2018100003558; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20181101 Effective date: 20191231 Free format text: TRIAL NUMBER: 2015100002535; TRIAL DECISION FOR INVALIDATION REQUESTED 20150410 Effective date: 20191231 Free format text: TRIAL NUMBER: 2018100003552; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20181101 Effective date: 20191231 Free format text: TRIAL NUMBER: 2018100003384; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20181019 Effective date: 20191231 Free format text: TRIAL NUMBER: 2018100003550; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20181101 Effective date: 20191231 Free format text: TRIAL NUMBER: 2018100003541; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20181101 Effective date: 20191231 Free format text: TRIAL NUMBER: 2018100003539; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20181101 Effective date: 20191231 Free format text: TRIAL NUMBER: 2018100003536; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20181101 Effective date: 20191231 Free format text: TRIAL NUMBER: 2018100003556; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20181101 Effective date: 20191231 Free format text: TRIAL NUMBER: 2018100003542; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20181101 Effective date: 20191231 Free format text: TRIAL NUMBER: 2015100002518; TRIAL DECISION FOR INVALIDATION REQUESTED 20150410 Effective date: 20191231 Free format text: TRIAL NUMBER: 2018100003548; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20181101 Effective date: 20191231 Free format text: TRIAL NUMBER: 2018100003554; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20181101 Effective date: 20191231 Free format text: TRIAL NUMBER: 2018100003562; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20181101 Effective date: 20191231 Free format text: TRIAL NUMBER: 2018100003540; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20181101 Effective date: 20191231 Free format text: TRIAL NUMBER: 2018100003537; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20181101 Effective date: 20191231 Free format text: TRIAL NUMBER: 2018100003543; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20181101 Effective date: 20191231 Free format text: TRIAL NUMBER: 2018100003546; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20181101 Effective date: 20191231 |
|
J202 | Request for trial for correction [limitation] | ||
J121 | Written withdrawal of request for trial | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2020105000054; TRIAL DECISION FOR CORRECTION REQUESTED 20200615 Effective date: 20200717 |
|
J302 | Written judgement (patent court) |
Free format text: TRIAL NUMBER: 2020200002727; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20200306 Effective date: 20210916 |